Involvement of bacterial resistances in community-acquired urinary infections;Implicaciones de las resistencias bacterianas en las infecciones urinarias adquiridas en la comunidad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 1, 2005, Pages 1-3

  Horcajada, Juan Pablo ^a   Fariñas, María Del Carmen ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFIXIME; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; FOSFOMYCIN; NALIDIXIC ACID; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL DISEASE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; COMMUNITY ACQUIRED URINARY TRACT INFECTION; DRUG EFFICACY; EDITORIAL; ENTEROBACTERIACEAE; ENZYME ACTIVITY; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; PYELONEPHRITIS; RISK FACTOR; URINARY TRACT INFECTION;

EID: 14644399204     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070400     Document Type: Editorial

References (49)

1. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281:736-9.
2. Kahlmeter G. The ECO.SENS project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother 2000;46(Suppl S1):15-22.
3. Nicolle L. Urinary tract infection: traditional pharmacologic therapies. Am J Med 2002;113:35S-44S.
4. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81.
5. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001;33:89-94.
6. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002;50:945-52.
7. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, et al. Empiric use of TMP-SMX in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34:1165-9.
8. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulphamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90.
9. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
10. Norris S, Mandell GL. The quinolones: history and overview. En: Andriole VT, editor. The quinolones. San Diego: Academic Press, 1988; p. 1-22.
11. The Sandford Guide to Antimicrobial Therapy 2004. En: Gilbert DN, Moellering RC Jr., Sande MA, editors. Vermont: Antimicrobial Therapy, 2004.
12. Mensa J, Gatell JM, Jiménez de Anta MT, Prats G, Dominguez-Gil A. Guía de terapéutica antimicrobiana 2004. Barcelona: Masson, 2004.
13. Peña C, Albareda JM, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-4.
14. Horcajada JP, Vila J, Moreno-Martínez A, Ruiz J, Martínez JA, Sánchez M, et al. Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother 2002;49:55-9.
15. Oteo J, Campos J. Uso de quinolonas y resistencia. Enferm Infecc Microbiol Clin 2004;22:201-3.
16. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999;43:2736-41.
17. Killgore K, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004;38:1148-52.
18. Pardo FJ, Moreno R, Sabater S, González F, Borrell C, Barreda A. Aspectos epidemiológicos de la resistencia de Escherichia coli a ciprofloxacino en un hospital general. Rev Esp Quimioterap 2000;13:44-50.
19. Horcajada JP, Moreno I, Velasco M, Martínez JA, Moreno-Martínez A, Barranco M, et al. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. J Intern Med 2003;254:280-6.
20. Sanchez M, Collvinent B, Miró O, Horcajada JP, Moreno A, Marco F, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomized controlled trial. Emerg Med J 2002;19:19-22.
21. Bloomfield P, Hodson EM, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 2003;CD003772.
22. Hooton TM, Stamm WE. The vaginal flora and urinary tract infections. En: Mobley HLT, Warren JW, editors. Urinary tract infections: molecular pathogenesis and clinical management. Washington: American Society for Microbiology Press, 1996; p. 67-94.
23. Horcajada JP, Smithson A. Acute pyelonephritis: an update. Rev Med Microbiol 2003;14:119-26.
24. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71.
25. Bermejo J, Lesnaberes P, Arnesi N, Gianello M, Notario R, Borda N, et al. Factores de riesgo asociados con las infecciones debidas a Klebsiella pneumoniae resistentes a ceftazidima. Enferm Infecc Microbiol Clin 2003;21:72-6.
26. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
27. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-23.
28. Rodríguez-Baño J, Navarro MD, Romero L, Martínez- Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94.
29. Hernández JR, Pascual A, Cantón R, Martínez- Martínez L y Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003;21:77-82.
30. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-7.
31. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-8.
32. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-9.
33. Martínez-Martínez L, Pascual A, Conejo MC, García I, Joyanes P, Doménech-Sánchez A, et al. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother 2002;46:3926-32.
34. Paterson DL, Singh N, Gayowsky T, Marino IR. Fatal infection due to extended-espectrum beta-lactamase producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin Infect Dis 1999;28:683-4.
35. Livermore D, Oakton KJ, Carter MW, Warner M. Activity of Ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 2001;45:2831-7.
36. Alhambra A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alós JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004;53:1090-4.
37. Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, et al. Pharmacokinetics of Ertapenem in healthy young volunteers. 41st ICAAC. Chicago, Illinois, USA, December 16-19 2001 (abstract A-939).
38. Mouton JW, Touw DJ, Horrevorts AM, Vinks A. Comparative pharmacokinetics of the carbapenemes. Clinical Implications. Clin Pharmacokinet 2000;39:185-201.
39. Jiménez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002;60:16-22.
40. Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind, multicenter study. Antimicrob Agents Chemother 2002;46:2895-900.
41. Andreu A, Alós JI, Gobernado M, Marco F, De la Rosa M, García-Rodríguez JA, et al. Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio nacional multicéntrico. Enf Inf Microb Clin 2004;23:4-9.
42. Naber KG, Thyroff-Friesinger U. Fosfomycin trometamol versus ofloxacin/ co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study. Infection 1990;18:S70-6.
43. Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection 1990;18(Suppl 2): S89-S93.
44. Fosfomycin for urinary tract infections. Med Lett 1997;39:66-8.
45. Hooton TM, Beeser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004;39:75-80.
46. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003;22(Suppl 2):53-9.
47. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003;47:2850-8.
48. Velasco M, Horcajada JP, Mensa J, Moreno-Martínez A, Vila J, Martínez JA, et al. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis 2001;33:1682-6.
49. Vila J, Simon K, Ruiz J, Horcajada JP, Velasco M, Barranco M, et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis 2002;186:1039-42.